Abstract
Purpose To evaluate the clinical utility of visible light optical coherence tomography (VIS-OCT) and to test whether VIS-OCT reflectivity and spectroscopy of peripapillary retinal nerve fiber layer (pRNFL) are correlated with severity of glaucoma, compared with standard-of-care OCT thickness measurements.
Design Cross-sectional study.
Method Fifty-four eyes from three groups of subjects (normal, glaucoma suspect, and glaucoma) were scanned by a custom-designed dual-channel device that simultaneously acquired visible (VIS-OCT) and near-infrared OCT (NIR-OCT) images. A 5×5 mm2 scan was taken of the peripapillary nerve fiber layer (pRNFL).
The pRNFL reflectivity was calculated for both channels and the spectroscopic marker was quantified by pVN, defined by the ratio of VIS-OCT to NIR-OCT pRNFL reflectivity. The results were compared with ophthalmic exams and clinical Zeiss OCT measurements. Mixed linear model was used to evaluate the association of imaging markers with glaucoma severity.
Results VIS-OCT pRNFL reflectivity significantly, se uentially declined from normal to suspect to glaucoma (3.42 ± 0.35, 2.58 ± 0.37, 2.16 ± 0.39, mean ± SD), as did NIR-OCT pRNFL reflectivity (2.46 ± 0.24, 2.27 ± 0.24, 1.96 ± 0.25). The pVN also had the same decreasing trend among three groups (1.39 ± 0.08, 1.14 ± 0.08, 1.08 ± 0.10). Normal and suspect eyes were significantly different in VIS-OCT pRNFL reflectivity (p=0.002), pVN (p<0.001) but not in NIR-OCT pRNFL reflectivity (p=0.14), circumpapillary RNFL (cpRNFL) thickness (p=0.17), or macular ganglion cell layer and inner plexiform layer (GCL+IPL) thickness (p=0.07) in the mixed linear model.
Conclusion VIS-OCT pRNFL reflectivity and pVN was more sensitive in separating suspect eyes from normal ones than clinical OCT thickness measurements. VIS-OCT pRNFL reflectivity and pVN could be a useful metric in early detection of glaucoma upon further longitudinal validation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by BrightFocus foundation (G2017077), NEI/NINDS R01NS108464
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Boston Medical Center IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
